Immunotherapy Complications in the ICU: Recognition, Management, and Critical Pearls for the Intensivist

DR Neeraj Manikath , claude.ai

Abstract

Background: Immune checkpoint inhibitors (ICIs) have revolutionized cancer treatment but present unique challenges in the intensive care unit (ICU). Immune-related adverse events (irAEs) can mimic sepsis and other critical illnesses, leading to diagnostic delays and inappropriate treatment.

Objective: To provide critical care physicians with practical guidance for recognizing, diagnosing, and managing ICI-related complications in the ICU setting.

Key Points: Early recognition of irAEs, particularly pneumonitis, colitis, and myocarditis, is crucial. Corticosteroids remain first-line therapy, with biologics reserved for steroid-refractory cases. The sepsis mimicry phenomenon requires heightened clinical suspicion and systematic approach.

Keywords: Immune checkpoint inhibitors, immune-related adverse events, critical care, sepsis mimicry, immunosuppression

Introduction

The advent of immune checkpoint inhibitors (ICIs) including anti-PD-1 (pembrolizumab, nivolumab), anti-PD-L1 (atezolizumab, durvalumab), and anti-CTLA-4 (ipilimumab) agents has transformed oncological care. However, by unleashing the immune system against cancer cells, these agents can trigger immune-related adverse events (irAEs) affecting virtually any organ system. Critical care physicians increasingly encounter these complications, which can be life-threatening and require immediate recognition and management.

The incidence of severe (grade 3-4) irAEs ranges from 10-20% with single-agent therapy to 40-60% with combination regimens. ICU admission rates for ICI patients range from 5-15%, with mortality rates of 20-40% in this population. Understanding the unique pathophysiology, clinical presentations, and management strategies is essential for modern intensivists.

Pathophysiology of Immune-Related Adverse Events

ICIs work by blocking inhibitory checkpoints (PD-1, PD-L1, CTLA-4) that normally prevent excessive immune activation. While this enhances anti-tumor immunity, it simultaneously reduces immune tolerance, potentially triggering autoimmune-like reactions against healthy tissues.

The mechanism involves:

Loss of peripheral immune tolerance
Molecular mimicry between tumor and self-antigens
Enhanced T-cell activation and proliferation
Increased cytokine production (IL-17, IFN-γ, TNF-α)
Tissue infiltration by activated immune cells

This pathophysiology explains why irAEs can affect any organ system and why they often respond to immunosuppressive therapy rather than antimicrobials.

Clinical Pearls: Recognizing Major irAEs

Pearl 1: ICI-Related Pneumonitis

Clinical Presentation:

Insidious onset dyspnea, dry cough, fatigue
Can present as acute respiratory failure requiring mechanical ventilation
Fever in only 20-30% of cases (unlike infectious pneumonia)
Median onset: 2-6 months after ICI initiation

Diagnostic Approach:

High-resolution CT chest: Ground-glass opacities, organizing pneumonia pattern, or hypersensitivity pneumonitis appearance
Bilateral infiltrates in 60-80% of cases
BAL fluid: Lymphocytic predominance (>40%), elevated CD4/CD8 ratio
Exclude infection: Negative bacterial cultures, pneumocystis PCR, viral studies

Grading System:

Grade 1: Asymptomatic, radiographic changes only
Grade 2: Symptomatic, limiting activities of daily living
Grade 3: Severe symptoms, limiting self-care, oxygen required
Grade 4: Life-threatening, ventilatory support needed

Pearl 2: ICI-Related Colitis

Clinical Presentation:

Diarrhea (>6 stools/day), abdominal pain, hematochezia
Can progress to toxic megacolon, perforation
Median onset: 6-12 weeks after ICI initiation
May present with dehydration, electrolyte abnormalities

Diagnostic Approach:

Stool studies: C. difficile toxin, bacterial culture, ova and parasites
Colonoscopy: Skip lesions, ulcerations, lymphocytic infiltration
Histology: Increased intraepithelial lymphocytes, cryptitis, surface epithelial damage
CT abdomen: Wall thickening, pneumatosis (severe cases)

Grading:

Grade 1: <4 stools/day above baseline
Grade 2: 4-6 stools/day above baseline, mucus/blood
Grade 3: ≥7 stools/day, incontinence, hospitalization needed
Grade 4: Life-threatening consequences, perforation, ischemia

Pearl 3: ICI-Related Myocarditis

Clinical Presentation:

Chest pain, dyspnea, fatigue, palpitations
Can present as cardiogenic shock, sudden cardiac death
Median onset: 27-34 days (earlier than other irAEs)
Often concurrent with myasthenia gravis, myositis

Diagnostic Approach:

Cardiac biomarkers: Troponin elevation (>99th percentile)
ECG: Non-specific changes, arrhythmias, conduction abnormalities
Echocardiogram: Wall motion abnormalities, reduced ejection fraction
Cardiac MRI: T2-weighted hyperintensity, late gadolinium enhancement
Endomyocardial biopsy: Gold standard but high-risk in acute setting

High-Risk Features:

Complete heart block, sustained ventricular tachycardia
Ejection fraction <40%
Concurrent neurologic irAEs (myasthenia gravis)
Elevated troponin >10x upper limit of normal

Oysters: The Sepsis Mimicry Phenomenon

Why irAEs Mimic Sepsis

Many irAEs present with systemic inflammatory response syndrome (SIRS) criteria, creating diagnostic confusion:

Common Overlapping Features:

Fever, tachycardia, tachypnea
Leukocytosis or leukopenia
Elevated lactate, procalcitonin
Multi-organ dysfunction
Hypotension, altered mental status

Key Differentiating Features:

Parameter	Sepsis	irAEs
Onset	Acute (hours-days)	Subacute (days-weeks)
Fever pattern	High, persistent	Low-grade, intermittent
Procalcitonin	Markedly elevated (>2 ng/mL)	Mildly elevated (<0.5 ng/mL)
Response to antibiotics	Improvement within 48-72h	No improvement
Organ involvement	Sequential failure	Concurrent, specific patterns
CRP	Very high (>150 mg/L)	Moderately elevated

Diagnostic Approach to Suspected irAEs

Step 1: Clinical Suspicion

Recent ICI therapy (within 2 years)
Temporal relationship to treatment
Organ-specific symptoms not explained by infection

Step 2: Systematic Evaluation

Complete infectious workup (blood, urine, respiratory cultures)
Procalcitonin, CRP, lactate
Organ-specific investigations based on presentation
Consider concurrent sepsis (10-15% of cases)

Step 3: Multidisciplinary Approach

Early oncology consultation
Infectious disease involvement
Organ-specific specialists (cardiology, pulmonology, gastroenterology)

Management Hacks: When and How to Treat

Hack 1: Steroid Initiation Guidelines

Immediate Steroid Therapy (Within 24-48 hours):

Grade 3-4 irAEs of any type
Grade 2 pneumonitis, myocarditis, or neurologic irAEs
Any irAE with organ failure or life-threatening features

Steroid Dosing Protocol:

Grade 2 irAEs: Prednisolone 1-2 mg/kg/day (max 80mg)
Grade 3-4 irAEs: Methylprednisolone 1-2 mg/kg/day IV
Myocarditis: Methylprednisolone 1000mg IV daily x 3-5 days

Steroid Tapering:

Continue full dose until improvement to grade 1 or baseline
Taper by 50% weekly until 10mg prednisolone equivalent
Then taper by 5mg weekly until discontinuation
Total duration: Usually 6-12 weeks minimum

Hack 2: Second-Line Immunosuppression

Indications for Additional Therapy:

No improvement after 48-72 hours of high-dose steroids
Worsening despite appropriate steroid therapy
Steroid-dependent disease (unable to taper below 10mg/day)
Contraindications to prolonged steroids

Agent Selection by irAE Type:

Pneumonitis:

First choice: Infliximab 5mg/kg IV (avoid if active infection)
Alternative: Mycophenolate mofetil 1000mg BID
Refractory: Rituximab, cyclophosphamide

Colitis:

First choice: Infliximab 5mg/kg IV
Alternative: Vedolizumab (gut-selective)
Severe cases: Fecal microbiota transplantation

Myocarditis:

First choice: Abatacept 10mg/kg IV
Alternative: Alemtuzumab, ATG
Refractory: Plasmapheresis, IVIG

Hack 3: Supportive Care Strategies

Infection Prevention:

Pneumocystis prophylaxis (TMP-SMX or atovaquone)
Monitor for opportunistic infections
Consider antiviral prophylaxis in high-risk patients

Monitoring Parameters:

Daily: Vitals, organ function, inflammatory markers
Weekly: Complete blood count, comprehensive metabolic panel
Steroid side effects: Glucose, bone density, psychiatric symptoms

ICU-Specific Considerations:

Avoid nephrotoxic agents in acute kidney injury
Early enteral nutrition to prevent gut translocation
DVT prophylaxis (higher risk with steroids and malignancy)
Stress ulcer prophylaxis

Special Populations and Scenarios

Combination Immunotherapy

Higher incidence of irAEs (55-95% vs 15-20% monotherapy)
Earlier onset and greater severity
Multiple simultaneous irAEs common
May require combination immunosuppressive therapy

Pre-existing Autoimmune Disease

Not an absolute contraindication for ICIs
Higher risk of irAEs and autoimmune flares
Baseline immunosuppression may mask early irAEs
Require careful monitoring and lower threshold for treatment

Post-Transplant Patients

Risk of transplant rejection with ICI therapy
Immunosuppressive agents may reduce both irAE risk and efficacy
Close coordination with transplant team essential
Consider alternative cancer therapies when possible

Prognosis and Long-term Outcomes

Recovery Patterns:

Most irAEs (70-80%) resolve with appropriate immunosuppression
Endocrine irAEs often permanent (hypothyroidism, diabetes)
Neurologic irAEs have variable recovery (30-70%)
Myocarditis mortality remains high (25-50%)

ICI Rechallenge:

Safe in grade 1-2 irAEs after resolution
Generally contraindicated after grade 3-4 events
Never rechallenge after myocarditis or severe neurologic irAEs
Consider alternative ICI agents (anti-PD-1 vs anti-CTLA-4)

Quality Improvement and System Approaches

Early Recognition Systems

Electronic health record alerts for ICI patients
Standardized assessment tools for irAE screening
Education programs for emergency and ICU staff
Rapid access to oncology consultation

Multidisciplinary Care Models

ICI toxicity committees with multispecialty representation
Standardized treatment protocols and order sets
Regular case review and outcome monitoring
Patient and family education programs

Future Directions and Emerging Therapies

Biomarkers for Prediction:

Genetic polymorphisms (HLA types, cytokine genes)
Baseline immune profiling (T-regulatory cells, cytokines)
Early inflammatory markers (IL-17, IFN-γ signature)

Novel Therapeutic Approaches:

Selective immunomodulators (JAK inhibitors, sphingosine-1-phosphate modulators)
Combination prevention strategies
Personalized immunosuppression based on irAE type and severity

Artificial Intelligence Applications:

Predictive models for irAE development
Automated screening and monitoring systems
Treatment response prediction algorithms

Summary and Key Takeaways

High Index of Suspicion: Any ICU patient with recent ICI exposure presenting with SIRS should be evaluated for irAEs, not just sepsis.
Organ-Specific Recognition: Pneumonitis (ground-glass opacities, lymphocytic BAL), colitis (inflammatory pattern, negative infectious workup), and myocarditis (troponin elevation, conduction abnormalities) have characteristic features.
Early Aggressive Treatment: High-dose corticosteroids should be initiated promptly for grade 3-4 irAEs or any life-threatening manifestation.
Steroid-Refractory Disease: Second-line agents (infliximab, mycophenolate, abatacept) should be considered early in non-responders.
Multidisciplinary Approach: Close collaboration with oncology, infectious diseases, and organ specialists is essential for optimal outcomes.
Infection Vigilance: Immunosuppressive therapy increases infection risk; maintain high suspicion and provide appropriate prophylaxis.
Long-term Planning: Most irAEs require prolonged immunosuppression (6-12 weeks minimum) with careful monitoring for complications.

The management of ICI-related complications requires a paradigm shift from traditional infectious disease approaches to immunologically-focused care. As these agents become increasingly common in oncological practice, critical care physicians must develop expertise in recognizing and managing these unique complications to optimize patient outcomes.

References

Brahmer JR, et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2018;36(17):1714-1768.
Haanen JBAG, et al. Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017;28(suppl_4):iv119-iv142.
Zhang L, et al. Immune-related adverse events in the ICU: A systematic review and meta-analysis. Critical Care Medicine. 2022;50(3):e234-e245.
Johnson DB, et al. Fulminant myocarditis with combination immune checkpoint blockade. N Engl J Med. 2016;375(18):1749-1755.
Nishino M, et al. Drug-related pneumonitis in the era of precision cancer therapy. JCO Precision Oncology. 2017;1:1-16.
Wang GX, et al. Immune checkpoint inhibitor cancer therapy: spectrum of imaging findings. Radiographics. 2017;37(7):2132-2144.
Dougan M, et al. AGA Institute Clinical Guidelines Committee. AGA Clinical Practice Update on Diagnosis and Management of Immune Checkpoint Inhibitor Colitis and Hepatitis. Gastroenterology. 2021;160(4):1384-1393.
Lyon AR, et al. Immune checkpoint inhibitors and cardiovascular toxicity. Lancet Oncol. 2018;19(9):e447-e458.
Cortellini A, et al. Correlations Between the Immune-related Adverse Events Spectrum and Efficacy of Anti-PD1 Immunotherapy in NSCLC Patients. Clin Lung Cancer. 2019;20(4):237-247.
Kumar V, et al. Current diagnosis and management of immune related adverse events (irAEs) induced by immune checkpoint inhibitor therapy. Front Pharmacol. 2017;8:49.
Menzies AM, et al. Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab. Ann Oncol. 2017;28(2):368-376.
Schneider BJ, et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update. J Clin Oncol. 2021;39(36):4073-4126.
Martins F, et al. Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance. Nat Rev Clin Oncol. 2019;16(9):563-580.
Thompson JA, et al. Management of immunotherapy-related toxicities, version 1.2019. J Natl Compr Canc Netw. 2019;17(3):255-289.
Wang Y, et al. Treatment-related adverse events of PD-1 and PD-L1 inhibitors in clinical trials: a systematic review and meta-analysis. JAMA Oncol. 2019;5(7):1008-1019.

Conflict of Interest: The authors declare no conflicts of interest.
Funding: No specific funding was received for this work.

learningmedicine

Sunday, September 14, 2025